关键词: font-size:medium, ">茵芪肝复颗粒；异甘草酸镁；肝硬化；肝功能；炎症因子

Abstract: Objective： To observe the clinical effect of Yinqi Ganfu Granules combined with magnesium isoglycyrrhizinate in the treatment of hepatitis B cirrhosis (HBC). Methods： A total of 75 patients with HBC in the Xinyang Third People′s Hospital from March 2021 to July 2022 were selected. Patients were divided into a control group and an observation group according to different treatment plans. Among them， 38 cases were given magnesium isoglycyrrhizinate as the control group， and 37 cases were given Yinqi Ganfu Granules combined with magnesium isoglycyrrhizinate as the observation group. The clinical efficacy and adverse reaction rates of the two groups were compared， as well as the liver function and serum factor levels before and after 3 months of treatment. Results： The total clinical effective rate of the observation group was 91.89%， which was higher than that of the control group (73.68%) (P<0.05). After 3 months of treatment， the levels of alanine aminotransferase (ALT)， total bilirubin (TBIL)， and aspartate aminotransferase (AST) in the observation group were lower than those in the control group (P<0.05). After 3 months of treatment， the levels of high-sensitivity C-reactive protein (hs-CRP)， tumor necrosis factor (TNF)-α， advanced oxidation protein products (AOPP)， and total antioxidant capacity (TAOC) in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion： Yiqi Ganfu Granules combined with magnesium isoglycyrrhizinate has significant therapeutic effect on HBC， which can improve liver function， inhibit the level of inflammatory factors in the body， alleviate oxidative stress damage.

Key words: font-size:medium, ">Yinqi Ganfu Granules； Magnesium isoglycyrrhizinate； Cirrhosis； Liver function； Inflammatory factors